Cargando…

Plasma ropivacaine concentration after TAP block in a patient with cardiac and renal failure

We report a successful ultrasound-guided transversus abdominis plane (TAP) block as an analgesic option for minor abdominal surgery in a 66-year-old patient with cardiac, respiratory, and renal dysfunction caused by primary systemic amyloidosis. Bilateral TAP blocks with 120 mg (1.8 mg/kg) of ropiva...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Takashi, Tanaka, Satoshi, Sakamoto, Akiyuki, Hirabayashi, Takanobu, Kawamata, Mikito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159791/
https://www.ncbi.nlm.nih.gov/pubmed/30288098
http://dx.doi.org/10.2147/LRA.S173877
_version_ 1783358657602256896
author Ishida, Takashi
Tanaka, Satoshi
Sakamoto, Akiyuki
Hirabayashi, Takanobu
Kawamata, Mikito
author_facet Ishida, Takashi
Tanaka, Satoshi
Sakamoto, Akiyuki
Hirabayashi, Takanobu
Kawamata, Mikito
author_sort Ishida, Takashi
collection PubMed
description We report a successful ultrasound-guided transversus abdominis plane (TAP) block as an analgesic option for minor abdominal surgery in a 66-year-old patient with cardiac, respiratory, and renal dysfunction caused by primary systemic amyloidosis. Bilateral TAP blocks with 120 mg (1.8 mg/kg) of ropivacaine provided sufficient intra- and postoperative analgesia for insertion of a continuous ambulatory peritoneal dialysis catheter. However, the plasma concentration of ropivacaine reached a maximum of 2.5 µg/mL at 15 minutes after the TAP block, a concentration that was potentially neurotoxic. Although apparent signs of local anesthetic systemic toxicity (LAST) such as convulsion or changes in an electrocardiogram were not observed, the patient became drowsy after the TAP block, which might be one of the mild symptoms of LAST. A TAP block by itself can thus be an anesthetic option for patients undergoing minor abdominal surgery. However, cardiac and renal dysfunction might influence the pharmacokinetics of a local anesthetic used, and attention should be paid to the possibility of LAST even with a low dose of a local anesthetic for patients with cardiac and renal failure.
format Online
Article
Text
id pubmed-6159791
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61597912018-10-04 Plasma ropivacaine concentration after TAP block in a patient with cardiac and renal failure Ishida, Takashi Tanaka, Satoshi Sakamoto, Akiyuki Hirabayashi, Takanobu Kawamata, Mikito Local Reg Anesth Case Report We report a successful ultrasound-guided transversus abdominis plane (TAP) block as an analgesic option for minor abdominal surgery in a 66-year-old patient with cardiac, respiratory, and renal dysfunction caused by primary systemic amyloidosis. Bilateral TAP blocks with 120 mg (1.8 mg/kg) of ropivacaine provided sufficient intra- and postoperative analgesia for insertion of a continuous ambulatory peritoneal dialysis catheter. However, the plasma concentration of ropivacaine reached a maximum of 2.5 µg/mL at 15 minutes after the TAP block, a concentration that was potentially neurotoxic. Although apparent signs of local anesthetic systemic toxicity (LAST) such as convulsion or changes in an electrocardiogram were not observed, the patient became drowsy after the TAP block, which might be one of the mild symptoms of LAST. A TAP block by itself can thus be an anesthetic option for patients undergoing minor abdominal surgery. However, cardiac and renal dysfunction might influence the pharmacokinetics of a local anesthetic used, and attention should be paid to the possibility of LAST even with a low dose of a local anesthetic for patients with cardiac and renal failure. Dove Medical Press 2018-09-21 /pmc/articles/PMC6159791/ /pubmed/30288098 http://dx.doi.org/10.2147/LRA.S173877 Text en © 2018 Ishida et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Ishida, Takashi
Tanaka, Satoshi
Sakamoto, Akiyuki
Hirabayashi, Takanobu
Kawamata, Mikito
Plasma ropivacaine concentration after TAP block in a patient with cardiac and renal failure
title Plasma ropivacaine concentration after TAP block in a patient with cardiac and renal failure
title_full Plasma ropivacaine concentration after TAP block in a patient with cardiac and renal failure
title_fullStr Plasma ropivacaine concentration after TAP block in a patient with cardiac and renal failure
title_full_unstemmed Plasma ropivacaine concentration after TAP block in a patient with cardiac and renal failure
title_short Plasma ropivacaine concentration after TAP block in a patient with cardiac and renal failure
title_sort plasma ropivacaine concentration after tap block in a patient with cardiac and renal failure
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159791/
https://www.ncbi.nlm.nih.gov/pubmed/30288098
http://dx.doi.org/10.2147/LRA.S173877
work_keys_str_mv AT ishidatakashi plasmaropivacaineconcentrationaftertapblockinapatientwithcardiacandrenalfailure
AT tanakasatoshi plasmaropivacaineconcentrationaftertapblockinapatientwithcardiacandrenalfailure
AT sakamotoakiyuki plasmaropivacaineconcentrationaftertapblockinapatientwithcardiacandrenalfailure
AT hirabayashitakanobu plasmaropivacaineconcentrationaftertapblockinapatientwithcardiacandrenalfailure
AT kawamatamikito plasmaropivacaineconcentrationaftertapblockinapatientwithcardiacandrenalfailure